Key result
Higher mean radiation doses to the heart, left ventricle, and left anterior descending artery were significantly associated with an increase in high-sensitivity cardiac troponin I.
Why the study?
Anti-HER2 therapy and left breast adjuvant RT can both cause cardiotoxicity, prompting evaluation of the influence of cardiac radiation doses on hs-cTnI values in patients receiving concurrent therapy.
Does higher cardiac radiation dose correlate with increased hscTnI in patients with left breast cancer undergoing concurrent anti-HER2 therapy and radiotherapy?
Observational (n=61)
Does higher cardiac radiation dose correlate with increased hscTnI in patients with left breast cancer undergoing concurrent anti-HER2 therapy and radiotherapy?
p-value: p=0.02
No takes yet. Share an insight, caveat, or question.
Higher radiation doses to the heart, left ventricle, and left anterior descending artery during left breast radiotherapy with concurrent anti-HER2 therapy are associated with early subclinical cardiotoxicity as measured by hscTnI elevation.
Antunac et al. (2023) conducted an observational in HER2-positive left breast cancer (n=61). Radiation dose to cardiac structures vs. Lower radiation dose was evaluated on Significant increase in hscTnI (>30% from baseline and ≥4 ng/L) (p=0.02). Higher mean radiation doses to the heart, left ventricle, and left anterior descending artery were significantly associated with an increase in high-sensitivity cardiac troponin I.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: